tnx-1300
Recombinant proteinexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2021 (NCT04996056)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Carboxylesterase 2Supplementation
CES2 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06045793 | Phase 2 | Dec 11, 2023 | National Institute on Drug Abuse (NIDA), Tonix Pharmaceuticals |
| NCT04996056 | Phase 2 | Aug 31, 2021 | Tonix Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tonix Pharmaceuticals | For profit | 2 | 2 | 1 | 2021 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1